Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Start-Up Spotlight: Embolx Believes Balloon Microcatheter Occlusion Will Be A 'Breakthrough' For BPH, Cancer

Executive Summary

Embolx is having a big year. US FDA cleared its Sniper balloon occlusion microcatheter for pressure-directed arterial embolization a few months after the UK's NICE issued recommendations supporting prostate artery embolization for lower urinary tract symptoms caused by benign prostatic hyperplasia. Now the company is focused on improving market penetration by investing in physician-education and supporting research on new applications of targeted embolization, hoping to attract commercial partners or a possible acquirer.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts